Summary
Cardinal Health, Inc. reported its financial results for the nine months ended March 31, 2006. Total revenue for the nine months increased by 9% to $59.7 billion, driven by growth across all reportable segments, particularly in Pharmaceutical Distribution and Provider Services. However, net earnings saw a significant decline of 14% to $679.1 million compared to the same period last year, primarily due to substantial losses from discontinued operations and increased selling, general, and administrative expenses, including a significant rise in equity-based compensation due to the adoption of SFAS No. 123(R). The company is undergoing significant restructuring and integration efforts, including a global restructuring program aimed at improving efficiency. The company is also navigating several legal and regulatory investigations, including an SEC investigation, and has reached an agreement-in-principle for a $35 million penalty. These factors, combined with changes in senior management, including the appointment of a new CEO, create a complex operating environment. Investors should monitor the company's ability to execute its restructuring plans, resolve ongoing investigations, and manage the impact of regulatory changes on its core businesses.
Key Highlights
- 1Total revenue increased by 9% year-over-year for the nine months ended March 31, 2006, reaching $59.7 billion, indicating continued top-line growth across business segments.
- 2Net earnings experienced a significant 14% decrease for the nine-month period, falling to $679.1 million, heavily impacted by substantial losses from discontinued operations and increased operating expenses.
- 3The company is actively engaged in a global restructuring program, with significant costs incurred for business consolidations, process improvements, and workforce reductions, expected to be substantially completed by the end of fiscal 2008.
- 4Equity-based compensation expense increased dramatically due to the adoption of SFAS No. 123(R), impacting reported earnings, with total expense for the nine months rising to $185.2 million from $7.2 million in the prior year.
- 5Cardinal Health is subject to an ongoing SEC investigation and other regulatory inquiries, with an agreement-in-principle reached for a $35 million penalty, though final settlement terms and potential additional liabilities remain uncertain.
- 6Significant assets and businesses have been classified as held for sale or discontinued operations, including portions of the Healthcare Marketing Services business and the United Kingdom-based Intercare Pharmaceutical Distribution business, leading to substantial impairment charges.
- 7The company announced leadership changes, appointing R. Kerry Clark as President and CEO, and Robert D. Walter as Executive Chairman, signaling a transition in executive management.